Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 52Squamous Cell Carcinoma of Head and Neck 26Carcinoma, Non-Small-Cell Lung 26Head and Neck Neoplasms 12Colonic Neoplasms 12Neoplasm Metastasis 11Neoplasms 10Rectal Neoplasms 9Pancreatic Neoplasms 9Lung Neoplasms 9Mouth Neoplasms 6Carcinoma, Squamous Cell 6Carcinoma 6Laryngeal Neoplasms 5Hypopharyngeal Neoplasms 5Oropharyngeal Neoplasms 4Thyroid Neoplasms 3Solid Tumors 3Ovarian Neoplasms 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Pancreatic Ductal 3Breast Neoplasms 3Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Laryngeal Diseases 2mCRC 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Panitumumab 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × Cetuximab × 90 days × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡